Skip to main content

Adicet Bio Inc(ACET-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.06
Day High7.36
Open:7.30
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Adicet Bio Inc

Select a category then submit the form to load news
Tipranks
JonesTrading Remains a Buy on Adicet Bio (ACET)
Tipranks
Adicet Bio advances prula-cel autoimmune Phase 1 program
Tipranks
Adicet Bio Implements Reverse Stock Split to Maintain Listing
Tipranks
Adicet Bio Shareholders Approve Flexible Reverse Stock Split
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)
Tipranks
Canaccord Genuity Reaffirms Their Buy Rating on Adicet Bio (ACET)
Tipranks
Adicet Bio Inc. Reports Q3 2025 Financial Results
Business Wire
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Business Wire
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
Tipranks
Adicet Bio (ACET) Receives a Hold from Citizens JMP
Tipranks
Truist Financial Remains a Buy on Adicet Bio (ACET)
Tipranks
Adicet Bio Receives Nasdaq Extension for Compliance
Tipranks
Guggenheim Sticks to Their Buy Rating for Adicet Bio (ACET)
Tipranks
Adicet Bio Announces Major Stock Offering Agreement
Tipranks
Adicet Bio Reports Promising Phase 1 Study Results
Business Wire
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
Business Wire
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Canaccord Genuity Sticks to Their Buy Rating for Adicet Bio (ACET)
Tipranks
Citizens JMP Reaffirms Their Hold Rating on Adicet Bio (ACET)
Business Wire
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Citizens JMP Sticks to Their Hold Rating for Adicet Bio (ACET)
Tipranks
Truist Financial Remains a Buy on Adicet Bio (ACET)
Tipranks
Canaccord Genuity Sticks to Its Buy Rating for Adicet Bio (ACET)
Tipranks
Adicet Bio Reports Q2 2025 Financial Results
Motley Fool
Adicet Bio (ACET) Q2 Loss Widens 3%
Business Wire
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Business Wire
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
Tipranks
Adicet Bio Announces 30% Workforce Reduction Strategy

Profile

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.